Randomized Trial of Finerenone on Urinary Albumin-to-Creatinine Ratio in Type 2 Diabetes Mellitus and CKD

2026/04/16 by Atsushi Tanaka, Takumi Imai, Muthiah Vaduganathan +27 · 1 voice
Medicine · #Chronic Kidney Disease and Diabetes #Blood Pressure and Hypertension Studies #Hormonal Regulation and Hypertension

paper · pdf · doi:10.1016/j.ekir.2026.106546

openalex publication_date 2026/04/16 · openalex created_date 2026/04/17 · openalex updated_date 2026/07/23

Abstract

Finerenone improved kidney and cardiovascular outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) when coadministered with conventional renin-angiotensin system inhibitors (RASi).1 A mediation analysis using pooled data from placebo-controlled kidney and cardiovascular outcomes trials of finerenone in 12,512 patients with T2D and CKD revealed that early reduction in urinary albumin excretion largely explains finerenone’s therapeutic benefits in kidney outcomes.2

Citations

• Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
• Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both

Discussions

• Randomized Trial of #Finerenone on #Urinary Albumin-to-Creatinine Ratio in Type 2 #Diabetes Mellitus and #CKD https://doi.org/10.1016/j.ekir.2026.106546 #KIRResearchLetter [bsky, 1 points, 0 comments]

Related

• The Role of Finerenone in Cardiorenal Protection and Urine Albumin-to-Creatinine Ratio Modulation
• Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
• Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
• COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics
• Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial